香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確 性或完整性亦不發表任何聲明，亦明確表示概不就因本公佈全部或任何部份內容而產生或因 倚賴該等內容而引致之任何損失承擔任何責任。 Hong Kong Robotics Group Holding Limited 港仔機器人集團控股有限公司 （於百慕達註冊成立之有限公司） （股份代號：370） 委任非執行董事兼董事局副主席 港仔機器人集團控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董事」）局 （「董事局」）謹此宣佈，經提名委員會推薦，邱毅勇先生（「邱先生」）已獲委任為非執行董事兼 董事局副主席，自二零二五年九月二十三日起生效。 邱先生的個人履歷載列如下： 邱先生，69歲，在投資、經營管理、資本運作、企業併購等方面擁有逾40年的經驗。彼曾在二零 零二年至二零一六年擔任中國中信集團有限公司及中信資源有限公司（香港股份代號：1205） 的董事；二零一零年十月至二零一五年十月期間擔任南方錳業投資有限公司（前稱中信大錳控 股有限公司，香港股份代號：1091）的主席兼執行董事。彼從二零二五年三月起一直擔任勇利 投資集團有限公司 ...

Group 1 - The core point of the news is that 港仔机器人 (00370.HK) has signed a technology licensing agreement with 达闼, allowing its subsidiary to use approximately 1,780 patents and 110 software copyrights in the Greater China region [1][2] - The agreement includes exclusive rights to use humanoid robot operating systems and cloud brain platform-related IP, as well as non-exclusive rights to use intelligent joint technology and other core hardware technologies [1][2] - The licensing agreement is crucial for the company's strategic plan to develop and maintain its own humanoid robots for various applications, including education, healthcare, elderly care, and property management [2] Group 2 - The company aims to accelerate the development process, enhance the functionality and reliability of humanoid robots, and shorten the time to market through the use of the licensed IP [2] - The IP includes proprietary operating systems, cloud brain platforms, and robot operating licensing technologies, which are essential for creating precise and efficient robotic solutions [2] - The terms of the licensing agreement were negotiated fairly among the parties, and the board of directors believes that the agreement is fair and reasonable, aligning with the overall interests of the company and its shareholders [2]

Core Viewpoint - The company has signed a technology licensing agreement with Datar, allowing its subsidiary in Greater China to utilize approximately 1,780 patents and 110 software copyrights, which are crucial for the development of humanoid robots in various applications [1] Group 1: Technology Licensing Agreement - The agreement grants exclusive rights to use humanoid robot operating systems and cloud brain platform-related IP, as well as non-exclusive rights to humanoid robot smart joint technology and other core hardware technologies [1] - The licensing of intellectual property (IP) is essential for the company's strategic plan to develop and maintain its own humanoid robots [1] Group 2: Strategic Goals - The company aims to leverage the licensed IP to accelerate development, enhance functionality and reliability of humanoid robots, and shorten time to market [1] - The strategic focus includes applications in education, healthcare, elderly care, property management, and other real-life applications, aligning with the goal of being at the forefront of technological innovation in the robotics sector [1]

Core Viewpoint - The company has signed a technology licensing agreement that allows its subsidiary to utilize approximately 1,780 patents and 110 software copyrights in the Greater China region, which is crucial for its strategic development in humanoid robotics [1] Group 1: Technology Licensing Agreement - The agreement was signed between the company's subsidiary AI Group and its partner, allowing the use of significant intellectual property (IP) related to humanoid robotics [1] - The IP includes exclusive rights to humanoid robot operating systems and cloud brain platforms, as well as non-exclusive rights to smart joint technology and other core hardware technologies [1] Group 2: Strategic Development - The company aims to develop and maintain its own humanoid robots for applications in education, healthcare, elderly care, property management, and other real-life scenarios [1] - This initiative aligns with the company's goal of being at the forefront of technological innovation and seizing emerging market opportunities in the robotics sector [1] Group 3: Importance of IP - The IP obtained through the licensing agreement is essential for the successful implementation of the company's strategic plan [1] - By leveraging this IP, the company intends to accelerate development, enhance the functionality and reliability of humanoid robots, and shorten time-to-market [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確 性或完整性亦不發表任何聲明，亦明確表示概不就因本公佈全部或任何部份內容而產生或因 倚賴該等內容而引致之任何損失承擔任何責任。 Hong Kong Robotics Group Holding Limited 港仔機器人集團控股有限公司 （於百慕達註冊成立之有限公司） （股份代號：370） 持續關連交易 與達闥之技術許可協議 茲提述(a)本公司於二零二五年二月十八日刊發之自願性公佈，內容有關本公司與達闥於二 零二五年二月十四日訂立的合作框架協議；(b)本公司於二零二五年三月五日刊發之自願性 公佈，內容有關本公司之全資附屬公司AI集團與達闥於二零二五年三月五日訂立之合作協 議，內容有關（其中包括）以組建方式成立香港仔機器人作為合資公司，以發展與人形機器 人智能技術及產品有關的業務營運以及擬將達闥及其聯屬公司持有的若干IP許可授予香港 仔機器人於中國的全資附屬公司；及(c)本公司於二零二五年三月二十八日刊發之自願性公 佈，內容有關完成重組香港仔機器人為一間由本公司持有51%及達闥持有49%的合資公司及 有關日期為二零二五年三月五日之上 ...

Group 1 - The Hong Kong stock market saw a strong performance in robotics concept stocks, with notable gains from companies such as 首程控股 (up over 11%) and 德昌电机控股 (up over 6%) [1] - Tesla CEO Elon Musk announced plans for an internal meeting focusing on artificial intelligence, autonomous driving systems, and the production of the Optimus robot [1] - PharmAGRl has signed a letter of intent with Tesla to deploy up to 10,000 Optimus 3+ humanoid robots in its agricultural operations and pharmaceutical production [1] Group 2 - 首程控股 reported a year-to-date increase of 164.56% and a market capitalization of 21.756 billion [2] - 德昌电机控股 experienced a year-to-date increase of 287.95% with a market capitalization of 37.918 billion [2] - 速腾聚创 and 华虹半导体 also showed significant year-to-date increases of 46.97% and 160.05% respectively, with market capitalizations of 21.333 billion and 97.603 billion [2]

Group 1 - The robotics sector in the Hong Kong stock market has seen a significant rally, with notable gains in various companies [1] - Notable stock performances include: - 首程控股 (Shou Cheng Holdings) up by 11.39% - 德昌电机控股 (Dechang Motor Holdings) up by 6.51% - 速腾聚创 (Suteng Juchuang) up by 5.77% - 华虹半导体 (Huahong Semiconductor) up by 5.53% - 地平线机器人-W (Horizon Robotics) up by 4.11% [2] - The year-to-date performance of these stocks shows substantial increases, with some companies like 首程控股 and 德昌电机控股 seeing gains of 164.56% and 287.95% respectively [2] Group 2 - Tesla CEO Elon Musk announced plans to hold internal meetings focusing on artificial intelligence, autonomous driving systems, and the production of the Optimus robot [1] - PharmAGRl has signed a letter of intent with Tesla to deploy up to 10,000 units of the Optimus 3+ humanoid robots in its agricultural operations and pharmaceutical production [1]

Core Insights - The collaboration between 港仔机器人集团 and 美年健康 marks a significant shift in the global health industry, introducing AI-driven health services through a strategic partnership valued at over 800 million yuan [1][5]. Group 1: Partnership Overview - The partnership aims to deploy 20,000 "smart health robot examination centers" over the next three years, transforming health services by making them more accessible and convenient for the public [2][4]. - This initiative will create a vast "human-machine collaborative health service network," allowing individuals to receive health assessments in their workplaces, communities, and factories [2][4]. Group 2: Technological Integration - 港仔机器人的 advanced humanoid robots will integrate over 30 instant detection functions, providing comprehensive health data collection, while 美年健康 will leverage its expertise to analyze this data and offer personalized health plans [3][4]. - The "海睿OS" cloud-based medical brain will enable real-time data processing for millions of users, addressing healthcare disparities by providing high-quality health guidance even in remote areas [3][5]. Group 3: Market Impact - The collaboration combines 美年健康's extensive network of over 500 clinics and a large customer base with 港仔机器人的 cutting-edge technology, creating a differentiated service system in health management [4]. - This partnership is expected to reach 300,000 corporate users and millions of individual users, establishing a new standard for AI in healthcare and showcasing China's capabilities in the global medical AI landscape [5].

Core Viewpoint - The partnership between 港仔机器人 and 美年健康 marks a significant advancement in the integration of AI technology into health management, aiming to create a large-scale health service network utilizing intelligent robots [1] Company Summary - 港仔机器人 experienced a stock price increase of nearly 12% at the close, finishing up 5.43% at 1.36 HKD, with a trading volume of 25.586 million HKD [1] - The company has successfully delivered 1,000 quadruped robots to 香港通宏护卫, demonstrating its recognized commercial viability in the market [1] Industry Summary - The strategic cooperation agreement signed between 港仔机器人 and 美年健康 is valued at over 800 million RMB, representing a historic breakthrough in the health management sector with the introduction of "AI proactive health protection" [1] - Over the next three years, the partnership plans to deploy 20,000 "smart health robot examination centers," aiming to establish the largest "human-machine collaborative health service network" globally [1]

Group 1 - The core viewpoint of the article highlights the strategic partnership between 港仔机器人 (00370) and 美年健康 (002044.SZ), which is expected to leverage their respective strengths in the health management sector [1] - 港仔机器人 experienced a significant stock price increase, closing up 5.43% at 1.36 HKD, with a trading volume of 25.586 million HKD [1] - The partnership involves a commercial contract valued at over 800 million HKD, marking a historic breakthrough in integrating "embodied intelligent humanoid robots" with medical AI models into the health management field [1] Group 2 - 美年健康 operates over 500 offline branches and has a customer base in the millions, providing a nationwide channel network for the collaboration [1] - 港仔机器人 has successfully delivered 1,000 quadruped robots to Hong Kong Tonghong Security, demonstrating its recognized commercial deployment capabilities [1] - Over the next three years, the two companies plan to deploy 20,000 "smart health robot examination centers," creating the largest "human-machine collaborative health service network" globally [1]